“Elotuzumab: the first available immunotherapeutic arrow against relapsed-refractory Multiple Myeloma” (2017) European Journal of Oncology and Environmental Health, 22(2), pp. 65–70. Available at: https://mattioli1885journals.com/index.php/EJOEH/article/view/6857 (Accessed: 18 July 2024).